12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AFM13: Phase I data

An open-label, dose-escalation, U.S. and German Phase I trial in 28 patients with relapsed or refractory Hodgkin's lymphoma showed that AFM13 led to 2 partial responses and 14 cases of stable disease. Patients received 0.01-7 mg/kg weekly AFM13 for 4 weeks (n=24) or 4.5 mg/kg AFM13 twice a week for 4 weeks (n=4). In 13 patients that received AFM13 at doses of >1.5 mg/kg, 3 patients...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >